PMID- 19922329
OWN - NLM
STAT- MEDLINE
DCOM- 20101208
LR  - 20151119
IS  - 1744-2818 (Electronic)
IS  - 1350-6129 (Linking)
VI  - 16
IP  - 4
DP  - 2009 Dec
TI  - Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence 
      from gadolinium-enhanced cardiac magnetic resonance imaging in patients with 
      amyloidosis.
PG  - 187-95
LID - 10.3109/13506120903421538 [doi]
AB  - BACKGROUND: The prognostic value of NT-proBNP has been recognized in patients 
      with amyloidosis complicated by cardiac involvement. We aimed to use contrast 
      enhanced cardiac magnetic resonance imaging (CMR) to identify functional and 
      structural alterations related to levels of NT-proBNP better to understand the 
      mechanisms of its release in cardiac amyloidosis. METHODS AND RESULTS: CMR was 
      performed on a 1.5-T scanner in 34 patients with biopsy proven amyloid light 
      chain (AL; n = 27) or hereditary transthyretin related (TTR; n = 7) amyloidosis. 
      NT-proBNP was higher in patients with (n = 25) compared to patients without 
      cardiac involvement (n = 9) (2931 (IQR: 972-8629; min-max: 25-27,277) pg/ml vs. 
      177 (IQR: 71-1431; min-max: 22-7935) pg/ml, p = 0.008). ROC analysis identified a 
      NT-proBNP of <2426.5 pg/ml as optimal discriminator for event free survival (682 
      +/- 65 days). NT-proBNP did not correlate with LV- ejection fraction, 
      end-diastolic and end-systolic volumes or stroke volume. There was a moderate 
      correlation between NT-proBNP and LV-mass (R = 0.52, p = 0.003) and extent of 
      late gadolinium enhancement (LGE; R = 0.41, p = 0.04). CONCLUSIONS: This study 
      confirms the prognostic value of NT-proBNP in patients with AL and TTR 
      amyloidosis and provides the novel finding that NT-proBNP correlates with 
      surrogates of myocardial amyloid burden such as LV-mass and LGE, supporting the 
      concept of NT-proBNP as a biomarker reflecting the severity of cardiac amyloid 
      infiltration.
FAU - Lehrke, Stephanie
AU  - Lehrke S
AD  - Department of Medicine III, Division of Cardiology, University Hospital 
      Heidelberg, Heidelberg, Germany. stephanie.lehrke@med.uni-heidelberg.de
FAU - Steen, Henning
AU  - Steen H
FAU - Kristen, Arnt V
AU  - Kristen AV
FAU - Merten, Constanze
AU  - Merten C
FAU - Lossnitzer, Dirk
AU  - Lossnitzer D
FAU - Dengler, Thomas J
AU  - Dengler TJ
FAU - Katus, Hugo A
AU  - Katus HA
FAU - Giannitsis, Evangelos
AU  - Giannitsis E
LA  - eng
PT  - Journal Article
PL  - England
TA  - Amyloid
JT  - Amyloid : the international journal of experimental and clinical investigation : 
      the official journal of the International Society of Amyloidosis
JID - 9433802
RN  - 0 (Amyloid)
RN  - 0 (Contrast Media)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - AU0V1LM3JT (Gadolinium)
SB  - IM
MH  - Amyloid/metabolism
MH  - Amyloidosis/*blood/*pathology
MH  - Cardiomyopathies/*blood/*pathology
MH  - Contrast Media
MH  - Female
MH  - *Gadolinium
MH  - Humans
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
EDAT- 2009/11/20 06:00
MHDA- 2010/12/14 06:00
CRDT- 2009/11/20 06:00
PHST- 2009/11/20 06:00 [entrez]
PHST- 2009/11/20 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.3109/13506120903421538 [pii]
AID - 10.3109/13506120903421538 [doi]
PST - ppublish
SO  - Amyloid. 2009 Dec;16(4):187-95. doi: 10.3109/13506120903421538.